Portal de Periódicos da CAPES

Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial

2021; Oxford University Press; Volume: 43; Issue: 13 Linguagem: Inglês

10.1093/eurheartj/ehab790

1522-9645

Rafael Romaguera, Pablo Salinas, Josep Gómez‐Lara, Salvatore Brugaletta, Antonio Gómez‐Menchero, Miguel Romero, Sergio García‐Blas, Raymundo Ocaranza, Pascual Bordes, Marcelo Jiménez Kockar, Neus Salvatella, Víctor Alfonso Jiménez Díaz, Mar Alameda, Ramiro Trillo, Dae Hyun Lee, Pedro Martín, María López-Benito, Alfonso Freites, Virginia Pascual‐Tejerina, Felipe Hernández, Bruno García del Blanco, Mohsen Mohandes, Francisco Bosa, Eduardo Pinar, Gerard Roura, Josep Comín‐Colet, Antonio Fernández-Ortı́z, Carlos Macaya, Xavier Rosselló, Manel Sabaté, Stuart J. Pocock, Joan Antoni Gómez‐Hospital, Carlos Salazar, Luis Ortega‐Paz, José M. de la Torre Hernández, Armando Pérez de Prado, Juan Sanchís, Soledad Ojeda, José Luis Ferreiro, Montserrat Gracida, Lara Fuentes, Luis Teruel, Guillem Muntané‐Carol, Rocío Castillo-Poyo, Pilar Jiménez‐Quevedo, Ángel Cequier,

Cardiac Imaging and Diagnostics

Patients with diabetes mellitus are at high risk of adverse events after percutaneous revascularization, with no differences in outcomes between most contemporary drug-eluting stents. The Cre8 EVO stent releases a formulation of sirolimus with an amphiphilic carrier from laser-dug wells, and has shown clinical benefits in diabetes. We aimed to compare Cre8 EVO stents to Resolute Onyx stents (a contemporary polymer-based zotarolimus-eluting stent) in patients with diabetes.